Symbols / CNTB $2.60 +0.78% Connect Biopharma Holdings Limited
CNTB Chart
About
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Market Cap | 146.96M | Enterprise Value | 103.30M | Income | -55.48M | Sales | 64.00K | Book/sh | 0.74 | Cash/sh | 0.79 |
| Dividend Yield | — | Payout | 0.00% | Employees | 64 | IPO | — | P/E | — | Forward P/E | -3.48 |
| PEG | — | P/S | 2296.18 | P/B | 3.49 | P/C | — | EV/EBITDA | -1.80 | EV/Sales | 1614.12 |
| Quick Ratio | 3.27 | Current Ratio | 3.74 | Debt/Eq | 1.64 | LT Debt/Eq | — | EPS (ttm) | -1.00 | EPS next Y | -0.75 |
| EPS Growth | — | Revenue Growth | -100.00% | Earnings | 2026-03-31 | ROA | -46.13% | ROE | -82.72% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -907.41% | Profit Margin | 0.00% | Shs Outstand | 56.52M | Shs Float | 12.03M | Short Float | 1.58% |
| Short Ratio | 2.19 | Short Interest | — | 52W High | 3.82 | 52W Low | 0.65 | Beta | — | Avg Volume | 240.92K |
| Volume | 216.37K | Target Price | $7.90 | Recom | Strong_buy | Prev Close | $2.58 | Price | $2.60 | Change | 0.78% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-01 | reit | BTIG | Buy → Buy | $10 |
| 2026-03-31 | reit | BTIG | Buy → Buy | $10 |
| 2025-12-01 | init | Lake Street | — → Buy | $9 |
| 2025-11-13 | reit | BTIG | Buy → Buy | $10 |
| 2025-10-31 | init | BTIG | — → Buy | $10 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-17 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-04 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2023-09-13 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2023-02-08 | main | SVB Leerink | — → Outperform | $7 |
| 2022-06-02 | init | Cantor Fitzgerald | — → Overweight | $5 |
| 2022-05-05 | down | Piper Sandler | Overweight → Neutral | $2 |
| 2022-05-04 | main | SVB Leerink | — → Outperform | $9 |
| 2022-01-06 | main | SVB Leerink | — → Outperform | $22 |
| 2021-04-13 | init | Jefferies | — → Buy | $27 |
| 2021-04-13 | init | SVB Leerink | — → Outperform | $32 |
- CNTB | Connect Biopharma Holdings Limited Insider Trading - Quiver Quantitative Fri, 17 Apr 2026 14
- Connect Bio (CNTB) Stock: Market Efficiency (At Highs) 2026-04-20 - Volume Spike - Xã Vĩnh Công Mon, 20 Apr 2026 15
- Connect Biopharma raises $20.2M, extends cash runway into 2027 - Stock Titan Mon, 30 Mar 2026 07
- Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - MarketBeat hu, 02 Apr 2026 07
- Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - GlobeNewswire ue, 31 Mar 2026 07
- Should I buy Connect Biopharma Holdings (CNTB) - Zacks Investment Research Wed, 30 Jul 2025 07
- New asthma and COPD drug data arrive as Connect funds operations into 2027 - Stock Titan ue, 31 Mar 2026 07
- Q1 Earnings Estimate for CNTB Issued By HC Wainwright - MarketBeat Fri, 10 Apr 2026 07
- Connect Biopharma Announces $20.2 Million Private Placement Financing - GlobeNewswire Mon, 30 Mar 2026 07
- Entity tied to CNTB director James Huang buys 1.16M shares in open market - Stock Titan Wed, 01 Apr 2026 07
- Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat Sun, 05 Apr 2026 07
- Connect Biopharma Holdings (CNTB) insider-linked stake of 9.6% disclosed - Stock Titan ue, 14 Apr 2026 15
- Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat Wed, 01 Apr 2026 07
- An eczema drug kept nearly 9 in 10 patients almost clear at one year - Stock Titan Mon, 30 Mar 2026 07
- A 2-minute IV shot improved breathing fast in asthma and COPD - Stock Titan Mon, 30 Mar 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.06
-99.75%
|
26.03
|
0.00
|
0.00
|
| Operating Revenue |
|
0.06
-99.75%
|
26.03
|
0.00
|
0.00
|
| Operating Expense |
|
58.14
+19.91%
|
48.48
-29.79%
|
69.06
-40.73%
|
116.51
|
| Research And Development |
|
37.80
+29.20%
|
29.26
-44.80%
|
53.00
-45.15%
|
96.63
|
| Selling General And Administration |
|
20.34
+5.78%
|
19.23
+19.78%
|
16.05
-22.84%
|
20.81
|
| General And Administrative Expense |
|
20.34
+5.78%
|
19.23
+19.78%
|
16.05
-22.84%
|
20.81
|
| Other Gand A |
|
20.34
+5.78%
|
19.23
+19.78%
|
16.05
-22.84%
|
20.81
|
| Other Operating Expenses |
|
—
|
—
|
-1.58
-70.08%
|
-0.93
|
| Total Expenses |
|
58.14
+19.91%
|
48.48
-29.79%
|
69.06
-40.73%
|
116.51
|
| Operating Income |
|
-58.07
-158.66%
|
-22.45
+67.49%
|
-69.06
+40.73%
|
-116.51
|
| Total Operating Income As Reported |
|
-58.07
-158.66%
|
-22.45
+67.49%
|
-69.06
+42.12%
|
-119.32
|
| EBITDA |
|
-57.37
-163.26%
|
-21.79
+68.11%
|
-68.34
+41.46%
|
-116.74
|
| Normalized EBITDA |
|
-57.37
-163.26%
|
-21.79
+68.11%
|
-68.34
+39.94%
|
-113.78
|
| Reconciled Depreciation |
|
0.70
+6.67%
|
0.66
-8.33%
|
0.72
-30.16%
|
1.03
|
| EBIT |
|
-58.07
-158.66%
|
-22.45
+67.49%
|
-69.06
+41.36%
|
-117.77
|
| Total Unusual Items |
|
—
|
—
|
2.88
+197.16%
|
-2.96
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
2.88
+197.16%
|
-2.96
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-4.70
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
4.70
|
| Net Income |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Pretax Income |
|
-55.28
-258.86%
|
-15.40
+75.15%
|
-61.99
+47.38%
|
-117.79
|
| Net Non Operating Interest Income Expense |
|
2.27
-49.07%
|
4.45
-14.74%
|
5.22
+242.94%
|
1.52
|
| Interest Expense Non Operating |
|
—
|
—
|
0.02
+9.52%
|
0.02
|
| Net Interest Income |
|
2.27
-49.07%
|
4.45
-14.74%
|
5.22
+242.94%
|
1.52
|
| Interest Expense |
|
—
|
—
|
0.02
+9.52%
|
0.02
|
| Interest Income Non Operating |
|
2.27
-49.07%
|
4.45
-14.74%
|
5.22
+238.28%
|
1.54
|
| Interest Income |
|
2.27
-49.07%
|
4.45
-14.74%
|
5.22
+238.28%
|
1.54
|
| Other Income Expense |
|
0.52
-79.84%
|
2.59
+40.44%
|
1.85
+165.75%
|
-2.81
|
| Other Non Operating Income Expenses |
|
0.52
-79.84%
|
2.59
+40.44%
|
1.85
+1131.33%
|
0.15
|
| Gain On Sale Of Security |
|
—
|
—
|
2.88
+65.32%
|
1.74
|
| Tax Provision |
|
0.20
-11.66%
|
0.22
+85.83%
|
0.12
-59.73%
|
0.30
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.62
|
| Net Income Including Noncontrolling Interests |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Net Income From Continuing Operation Net Minority Interest |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Net Income From Continuing And Discontinued Operation |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Net Income Continuous Operations |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Normalized Income |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+46.35%
|
-115.75
|
| Net Income Common Stockholders |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Diluted EPS |
|
-1.00
-257.14%
|
-0.28
+75.22%
|
-1.13
+46.23%
|
-2.10
|
| Basic EPS |
|
-1.00
-257.14%
|
-0.28
+75.22%
|
-1.13
+46.23%
|
-2.10
|
| Basic Average Shares |
|
55.66
+0.81%
|
55.21
+0.27%
|
55.07
+0.18%
|
54.97
|
| Diluted Average Shares |
|
55.66
+0.81%
|
55.21
+0.27%
|
55.07
+0.18%
|
54.97
|
| Diluted NI Availto Com Stockholders |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.41%
|
-118.09
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
56.08
-44.64%
|
101.28
-20.48%
|
127.38
-26.80%
|
174.01
|
| Current Assets |
|
50.93
-47.47%
|
96.96
-20.88%
|
122.55
-21.33%
|
155.78
|
| Cash Cash Equivalents And Short Term Investments |
|
44.34
-52.68%
|
93.71
-20.79%
|
118.30
-22.38%
|
152.42
|
| Cash And Cash Equivalents |
|
38.34
-50.99%
|
78.23
-25.96%
|
105.66
+33.73%
|
79.01
|
| Cash Equivalents |
|
—
|
—
|
78.32
+326.38%
|
18.37
|
| Cash Financial |
|
—
|
—
|
27.69
-54.34%
|
60.64
|
| Other Short Term Investments |
|
6.00
-61.25%
|
15.48
+22.44%
|
12.64
-82.78%
|
73.41
|
| Receivables |
|
0.16
-84.68%
|
1.05
+199.43%
|
0.35
+51.29%
|
0.23
|
| Accounts Receivable |
|
0.01
-98.35%
|
0.79
|
0.00
|
—
|
| Other Receivables |
|
—
|
—
|
0.18
-23.28%
|
0.23
|
| Accrued Interest Receivable |
|
0.15
-43.51%
|
0.26
-25.36%
|
0.35
|
—
|
| Prepaid Assets |
|
6.40
+258.78%
|
1.78
-53.63%
|
3.85
+22.84%
|
3.13
|
| Other Current Assets |
|
0.03
-93.08%
|
0.42
+675.93%
|
0.05
|
—
|
| Total Non Current Assets |
|
5.15
+19.04%
|
4.32
-10.35%
|
4.82
-73.55%
|
18.23
|
| Net PPE |
|
4.46
+5.15%
|
4.24
-10.54%
|
4.74
-11.92%
|
5.38
|
| Gross PPE |
|
7.75
+12.83%
|
6.87
+1.45%
|
6.77
-3.30%
|
7.00
|
| Accumulated Depreciation |
|
-3.29
-25.23%
|
-2.63
-29.39%
|
-2.03
-25.29%
|
-1.62
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
1.19
+197.51%
|
0.40
|
| Machinery Furniture Equipment |
|
6.24
+6.74%
|
5.85
+2.94%
|
5.68
+1565.40%
|
0.34
|
| Construction In Progress |
|
—
|
—
|
0.00
|
0.00
|
| Other Properties |
|
0.65
+242.33%
|
0.19
-59.09%
|
0.46
-91.59%
|
5.49
|
| Leases |
|
0.86
+3.49%
|
0.83
+32.59%
|
0.63
-17.85%
|
0.76
|
| Goodwill And Other Intangible Assets |
|
0.04
-15.09%
|
0.05
-14.52%
|
0.06
-98.04%
|
3.17
|
| Other Intangible Assets |
|
—
|
—
|
0.06
-98.04%
|
3.17
|
| Investments And Advances |
|
—
|
—
|
0.00
-100.00%
|
9.44
|
| Non Current Accounts Receivable |
|
—
|
—
|
0.11
-32.08%
|
0.16
|
| Non Current Prepaid Assets |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Other Non Current Assets |
|
0.65
+1857.58%
|
0.03
+37.50%
|
0.02
-29.41%
|
0.03
|
| Total Liabilities Net Minority Interest |
|
14.10
+54.58%
|
9.12
-64.77%
|
25.88
+56.64%
|
16.52
|
| Current Liabilities |
|
13.61
+60.87%
|
8.46
-66.54%
|
25.29
+61.89%
|
15.62
|
| Payables And Accrued Expenses |
|
10.21
+112.62%
|
4.80
-50.17%
|
9.64
-37.58%
|
15.44
|
| Payables |
|
1.96
+474.27%
|
0.34
-84.52%
|
2.21
-84.89%
|
14.62
|
| Accounts Payable |
|
1.96
+474.27%
|
0.34
-84.52%
|
2.21
-81.49%
|
11.94
|
| Other Payable |
|
—
|
—
|
2.35
-12.33%
|
2.69
|
| Current Accrued Expenses |
|
8.25
+84.89%
|
4.46
-39.96%
|
7.43
+810.29%
|
0.82
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.91
-12.81%
|
3.34
+62.94%
|
2.05
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.32
+109.09%
|
0.15
-45.96%
|
0.28
+53.23%
|
0.19
|
| Current Capital Lease Obligation |
|
0.32
+109.09%
|
0.15
-45.96%
|
0.28
+53.23%
|
0.19
|
| Current Deferred Liabilities |
|
0.17
+1.83%
|
0.16
-98.77%
|
13.32
|
0.00
|
| Current Deferred Revenue |
|
0.17
+1.83%
|
0.16
-98.77%
|
13.32
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.48
-26.52%
|
0.66
+12.14%
|
0.58
-34.78%
|
0.90
|
| Long Term Debt And Capital Lease Obligation |
|
0.37
+1433.33%
|
0.02
-86.67%
|
0.18
-26.53%
|
0.24
|
| Long Term Capital Lease Obligation |
|
0.37
+1433.33%
|
0.02
-86.67%
|
0.18
-26.53%
|
0.24
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.41
-37.88%
|
0.65
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.41
-37.88%
|
0.65
|
| Other Non Current Liabilities |
|
0.11
-81.96%
|
0.63
+56.05%
|
0.41
|
—
|
| Stockholders Equity |
|
41.98
-54.45%
|
92.17
-9.19%
|
101.50
-35.55%
|
157.49
|
| Common Stock Equity |
|
41.98
-54.45%
|
92.17
-9.19%
|
101.50
-35.55%
|
157.49
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
58.59
+1.26%
|
57.86
+0.62%
|
57.51
+0.10%
|
57.45
|
| Ordinary Shares Number |
|
56.44
+1.97%
|
55.35
+0.45%
|
55.10
+0.11%
|
55.04
|
| Treasury Shares Number |
|
2.15
-14.53%
|
2.51
+4.49%
|
2.41
-0.06%
|
2.41
|
| Additional Paid In Capital |
|
444.18
+1.10%
|
439.36
+1.61%
|
432.40
-31.22%
|
628.66
|
| Retained Earnings |
|
-400.83
-16.06%
|
-345.36
-4.74%
|
-329.73
+31.28%
|
-479.84
|
| Gains Losses Not Affecting Retained Earnings |
|
-1.19
+28.51%
|
-1.67
-65.28%
|
-1.01
+86.79%
|
-7.63
|
| Treasury Stock |
|
0.18
+0.00%
|
0.18
+0.00%
|
0.18
+0.00%
|
0.18
|
| Other Equity Adjustments |
|
-1.19
+28.51%
|
-1.67
-65.28%
|
-1.01
+86.79%
|
-7.63
|
| Total Equity Gross Minority Interest |
|
41.98
-54.45%
|
92.17
-9.19%
|
101.50
-35.55%
|
157.49
|
| Total Capitalization |
|
41.98
-54.45%
|
92.17
-9.19%
|
101.50
-35.55%
|
157.49
|
| Working Capital |
|
37.32
-57.83%
|
88.50
-9.01%
|
97.26
-30.61%
|
140.16
|
| Invested Capital |
|
41.98
-54.45%
|
92.17
-9.19%
|
101.50
-35.55%
|
157.49
|
| Total Debt |
|
0.69
+287.64%
|
0.18
-61.72%
|
0.47
+7.89%
|
0.43
|
| Capital Lease Obligations |
|
0.69
+287.64%
|
0.18
-61.72%
|
0.47
+7.89%
|
0.43
|
| Net Tangible Assets |
|
41.94
-54.47%
|
92.11
-9.19%
|
101.44
-34.27%
|
154.33
|
| Tangible Book Value |
|
41.94
-54.47%
|
92.11
-9.19%
|
101.44
-34.27%
|
154.33
|
| Available For Sale Securities |
|
—
|
—
|
—
|
9.44
|
| Investmentin Financial Assets |
|
—
|
—
|
0.00
-100.00%
|
9.44
|
| Other Equity Interest |
|
—
|
—
|
19.73
+19.78%
|
16.47
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.21
-116.86%
|
-23.61
+50.54%
|
-47.74
+52.97%
|
-101.52
|
| Cash Flow From Continuing Operating Activities |
|
-51.21
-116.86%
|
-23.61
+50.54%
|
-47.74
+52.97%
|
-101.52
|
| Net Income From Continuing Operations |
|
-55.48
-255.00%
|
-15.63
+74.84%
|
-62.11
+47.28%
|
-117.79
|
| Depreciation Amortization Depletion |
|
0.70
+6.67%
|
0.66
-8.33%
|
0.72
-30.16%
|
1.03
|
| Depreciation |
|
—
|
—
|
0.98
-4.21%
|
1.02
|
| Amortization Cash Flow |
|
—
|
—
|
0.01
+0.00%
|
0.01
|
| Depreciation And Amortization |
|
0.70
+6.67%
|
0.66
-8.33%
|
0.72
-30.16%
|
1.03
|
| Amortization Of Intangibles |
|
—
|
—
|
0.01
+0.00%
|
0.01
|
| Other Non Cash Items |
|
—
|
—
|
-2.01
-50.79%
|
-1.33
|
| Stock Based Compensation |
|
3.73
-44.62%
|
6.73
+24.68%
|
5.40
-21.88%
|
6.91
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.23
|
0.00
-100.00%
|
4.70
|
| Operating Gains Losses |
|
0.04
+311.11%
|
0.01
-91.09%
|
0.10
+106.77%
|
-1.49
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
+95.45%
|
-0.02
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
0.00
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
-0.37
+75.02%
|
-1.47
|
| Gain Loss On Sale Of PPE |
|
0.04
+311.11%
|
0.01
-91.18%
|
0.10
|
0.00
|
| Change In Working Capital |
|
0.58
+103.74%
|
-15.49
-257.24%
|
9.85
+52.52%
|
6.46
|
| Change In Receivables |
|
0.78
+198.35%
|
-0.79
|
0.00
-100.00%
|
4.05
|
| Changes In Account Receivables |
|
0.78
+198.35%
|
-0.79
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-4.11
-330.12%
|
1.79
-51.65%
|
3.69
|
—
|
| Change In Payables And Accrued Expense |
|
4.98
+240.52%
|
-3.54
+50.87%
|
-7.21
-2396.19%
|
-0.29
|
| Change In Accrued Expense |
|
3.36
+300.24%
|
-1.68
+72.41%
|
-6.08
|
—
|
| Change In Payable |
|
1.62
+186.88%
|
-1.87
-64.35%
|
-1.14
-293.08%
|
-0.29
|
| Change In Account Payable |
|
1.62
+186.88%
|
-1.87
-64.35%
|
-1.14
-46.39%
|
-0.78
|
| Change In Other Working Capital |
|
-0.55
+95.84%
|
-13.17
-197.17%
|
13.55
|
—
|
| Change In Other Current Assets |
|
—
|
—
|
0.12
-95.55%
|
2.70
|
| Change In Other Current Liabilities |
|
-0.52
-328.19%
|
0.23
+224.73%
|
-0.18
|
—
|
| Investing Cash Flow |
|
9.82
+384.50%
|
-3.45
-104.60%
|
74.98
+186.94%
|
-86.24
|
| Cash Flow From Continuing Investing Activities |
|
9.82
+384.50%
|
-3.45
-104.60%
|
74.98
+186.94%
|
-86.24
|
| Net PPE Purchase And Sale |
|
-0.43
+42.40%
|
-0.75
-126.21%
|
2.86
+164.97%
|
-4.41
|
| Purchase Of PPE |
|
-0.43
+42.13%
|
-0.75
-825.93%
|
-0.08
+98.16%
|
-4.41
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
2.94
|
0.00
|
| Capital Expenditure |
|
-0.43
+42.13%
|
-0.75
-825.93%
|
-0.08
+98.16%
|
-4.41
|
| Net Investment Purchase And Sale |
|
10.25
+479.49%
|
-2.70
-103.75%
|
72.12
+188.12%
|
-81.84
|
| Purchase Of Investment |
|
-30.47
-97.20%
|
-15.45
+50.20%
|
-31.03
+73.27%
|
-116.06
|
| Sale Of Investment |
|
40.72
+219.37%
|
12.75
-87.64%
|
103.14
+201.36%
|
34.23
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
-0.08
|
—
|
| Financing Cash Flow |
|
1.09
+381.50%
|
0.23
+404.44%
|
0.04
+152.94%
|
-0.09
|
| Cash Flow From Continuing Financing Activities |
|
1.09
+381.50%
|
0.23
+404.44%
|
0.04
+152.94%
|
-0.09
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
-0.29
-30.63%
|
-0.22
|
| Repayment Of Debt |
|
—
|
—
|
-0.29
-30.63%
|
-0.22
|
| Long Term Debt Payments |
|
—
|
—
|
-0.29
-30.63%
|
-0.22
|
| Net Long Term Debt Issuance |
|
—
|
—
|
-0.29
-30.63%
|
-0.22
|
| Net Common Stock Issuance |
|
—
|
—
|
0.04
+144.44%
|
0.02
|
| Common Stock Payments |
|
—
|
—
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.09
+381.50%
|
0.23
+404.44%
|
0.04
-62.18%
|
0.12
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-40.30
-50.15%
|
-26.84
-198.36%
|
27.28
+114.52%
|
-187.85
|
| Effect Of Exchange Rate Changes |
|
0.41
+168.57%
|
-0.59
-4.75%
|
-0.57
+33.80%
|
-0.86
|
| Beginning Cash Position |
|
78.23
-25.96%
|
105.66
+33.84%
|
78.95
-70.51%
|
267.72
|
| End Cash Position |
|
38.34
-50.99%
|
78.23
-25.96%
|
105.66
+33.73%
|
79.01
|
| Free Cash Flow |
|
-51.64
-111.97%
|
-24.36
+49.06%
|
-47.82
+54.85%
|
-105.92
|
| Income Tax Paid Supplemental Data |
|
0.29
+163.06%
|
0.11
-7.50%
|
0.12
-74.03%
|
0.46
|
| Amortization Of Securities |
|
-0.77
-528.46%
|
-0.12
+92.78%
|
-1.70
|
—
|
| Common Stock Issuance |
|
—
|
—
|
0.04
+144.44%
|
0.02
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.04
+144.44%
|
0.02
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-01 View
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-30 View
- 8-K2025-12-23 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 8-K2025-09-16 View
- 10-Q2025-08-13 View
- 8-K2025-08-13 View
- 8-K2025-07-22 View
- 8-K2025-07-21 View
- 8-K2025-07-17 View
- 8-K2025-07-09 View
- 10-Q2025-05-15 View
- 8-K2025-05-15 View
- 8-K2025-05-14 View
- 8-K2025-05-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|